Eradicating infections and fighting antimicrobial resistance
Morning Meeting Presentation for SB1M
8 December 2021
Today's presenters
SoftOx Solutions AS
CEO Geir Almås
Finance
CFO Kristine Rød
SoftOxRespiratory Tract
CMO-SIS Dr Christopher Burton
Our purpose
MISSION
Helping the world fighting infections
- Viruses
- Biofilm Resistance
- Antimicrobial Resistance
VISION
To become a world-leading developer
of antimicrobial technology
Investment highlights
Proven technology that effectively eradicates bacteria and viruses without creating resistance and answers significant unmet needs
Market approval of winning the Norwegian and Swedish public hospital tenders and free to enter the market through The EU Commission's interpretation of the BPR
Experienced research and development team, with support from Bispebjerg Hospital and University of Copenhagen
85 filed patents worldwide and 57 granted patents addressing formulations, uses, methods and devices
Strong medical technology platform developed over 10+ years with numerous opportunities for future development products
Morning Meeting Presentation for SB1M
Reinforcing nature's own ability to eradicate unwanted microbes
HYPOCHLOROUS | ACETIC | |||
ACID | ACID | SOFTOX TECHNOLOGY | ||
Documented broad | Antimicrobial | |||
antimicrobial effect | stabilizer | Replicating millions of years of evolution | ||
Clinical Results show Superior Effect
Morning Meeting Presentation for SB1M
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
SoftOx Solutions AS published this content on 13 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 December 2021 09:45:07 UTC.